The composite solubility versus pH profile and its role in intestinal absorption prediction

The purpose of this study was to examine absorption of basic drugs as a function of the composite solubility curve and intestinally relevant pH by using a gastrointestinal tract (GIT) absorption simulation based on the advanced compartmental absorption and transit model. Absorption simulations were carried out for virtual monobasic drugs having a range of pKa, log D, and dose values as a function of presumed solubility and permeability. Results were normally expressed as the combination that resulted in 25% absorption. Absorption of basic drugs was found to be a function of the whole solubility/pH relationship rather than a single solubility value at pH 7. In addition, the parameter spaces of greatest sensitivity were identified. We compared 3 theoretical scenarios: the GIT pH range overlapping (1) only the salt solubility curve, (2) the salt and base solubility curves, or (3) only the base curve. Experimental solubilities of 32 compounds were determined at pHs of 2.2 and 7.4, and they nearly all fitted into 2 of the postulated scenarios. Typically, base solubilities can be simulated in silico, but salt solubilities at low pH can only be measured. We concluded that quality absorption simulations of candidate drugs in most cases require experimental solubility determination at 2 pHs, to permit calculation of the whole solubility/pH profile.

[1]  William H. Press,et al.  Numerical recipes , 1990 .

[2]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  J. Devane Oral drug delivery technology : Addressing the solubility/permeability paradigm , 1998 .

[4]  W H Streng,et al.  General treatment of pH-solubility profiles of weak acids and bases and the effects of different acids on the solubility of a weak base. , 1984, Journal of pharmaceutical sciences.

[5]  A. Beresford,et al.  The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.

[6]  Tommy Liljefors,et al.  Correlation of aqueous solubility of salts of benzylamine with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 2002, International journal of pharmaceutics.

[7]  B. Müller,et al.  Drug Liposome Partitioning as a Tool for the Prediction of Human Passive Intestinal Absorption , 1999, Pharmaceutical Research.

[8]  Ulf Norinder,et al.  Experimental and Computational Screening Models for Prediction of Aqueous Drug Solubility , 2002, Pharmaceutical Research.

[9]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[10]  G. Flynn,et al.  Solubility of organic hydrochlorides. , 1972, Journal of pharmaceutical sciences.

[11]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[12]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[13]  H Lennernäs,et al.  Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.

[14]  Veerabahu Shanmugasundaram,et al.  Estimation of Aqueous Solubility of Organic Compounds with QSPR Approach , 2002, Pharmaceutical Research.

[15]  J. Topliss,et al.  QSAR model for drug human oral bioavailability. , 2000, Journal of medicinal chemistry.

[16]  Thomas J. Raub,et al.  Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.

[17]  B. Schug,et al.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .